Health Care [ 11/12 ] | Health Care Technology [ 63/75 ]
NASDAQ | Common Stock
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers.
The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure.
The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.
Renalytix Plc was incorporated in 2018 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | 0.00 Increased by +100.00% | -0.07 Increased by +100.00% |
| Feb 13, 24 | -0.18 Increased by +35.71% | -0.09 Decreased by -100.00% |
| Nov 15, 23 | -0.22 Increased by +31.25% | -0.10 Decreased by -120.00% |
| Sep 28, 23 | -0.24 Decreased by -20.00% | -0.13 Decreased by -84.62% |
| Jun 9, 23 | -0.28 Increased by +30.00% | -0.11 Decreased by -154.55% |
| Mar 30, 23 | -0.28 Increased by +33.33% | -0.14 Decreased by -100.00% |
| Nov 30, 22 | -0.32 Decreased by -128.57% | -0.13 Decreased by -146.15% |
| Sep 8, 22 | -0.20 Increased by +16.67% | -0.19 Decreased by -5.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 724.00 K Increased by +39.77% | -12.11 M Decreased by -9.02% | Decreased by -1.67 K% Increased by +22.00% |
| Dec 31, 23 | 709.00 K Decreased by -2.07% | -8.48 M Increased by +29.91% | Decreased by -1.20 K% Increased by +28.43% |
| Sep 30, 23 | 459.00 K Decreased by -52.63% | -10.15 M Increased by +15.05% | Decreased by -2.21 K% Decreased by -79.34% |
| Jun 30, 23 | 518.00 K Decreased by -37.67% | -11.10 M Increased by +33.14% | Decreased by -2.14 K% Decreased by -7.25% |
| Mar 31, 23 | 518.00 K Decreased by -36.21% | -11.10 M Increased by +25.24% | Decreased by -2.14 K% Decreased by -17.19% |
| Dec 31, 22 | 724.00 K Decreased by -14.32% | -12.11 M Increased by +33.76% | Decreased by -1.67 K% Increased by +22.69% |
| Sep 30, 22 | 969.00 K Increased by +105.30% | -11.95 M Decreased by -95.79% | Decreased by -1.23 K% Increased by +4.63% |
| Jun 30, 22 | 831.00 K Increased by +76.06% | -16.61 M Decreased by -172.06% | Decreased by -2.00 K% Decreased by -54.53% |